JP7422666B2 - 睡眠時無呼吸を治療するための方法および組成物 - Google Patents
睡眠時無呼吸を治療するための方法および組成物 Download PDFInfo
- Publication number
- JP7422666B2 JP7422666B2 JP2020542075A JP2020542075A JP7422666B2 JP 7422666 B2 JP7422666 B2 JP 7422666B2 JP 2020542075 A JP2020542075 A JP 2020542075A JP 2020542075 A JP2020542075 A JP 2020542075A JP 7422666 B2 JP7422666 B2 JP 7422666B2
- Authority
- JP
- Japan
- Prior art keywords
- oxybutynin
- composition
- atomoxetine
- enantiomeric excess
- use according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 68
- 201000002859 sleep apnea Diseases 0.000 title claims description 8
- 238000000034 method Methods 0.000 title description 45
- XIQVNETUBQGFHX-QFIPXVFZSA-N (R)-oxybutynin Chemical compound C1([C@](O)(C(=O)OCC#CCN(CC)CC)C=2C=CC=CC=2)CCCCC1 XIQVNETUBQGFHX-QFIPXVFZSA-N 0.000 claims description 91
- VHGCDTVCOLNTBX-QGZVFWFLSA-N atomoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=CC=C1C VHGCDTVCOLNTBX-QGZVFWFLSA-N 0.000 claims description 47
- 229960002430 atomoxetine Drugs 0.000 claims description 46
- 208000001797 obstructive sleep apnea Diseases 0.000 claims description 29
- 238000011282 treatment Methods 0.000 claims description 20
- 238000009472 formulation Methods 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 15
- 238000013265 extended release Methods 0.000 claims description 12
- 239000012729 immediate-release (IR) formulation Substances 0.000 claims description 12
- 206010041235 Snoring Diseases 0.000 claims description 9
- 239000002775 capsule Substances 0.000 claims description 6
- 239000003937 drug carrier Substances 0.000 claims description 6
- 239000006187 pill Substances 0.000 claims description 6
- 239000003826 tablet Substances 0.000 claims description 6
- 239000004480 active ingredient Substances 0.000 claims description 5
- 239000006186 oral dosage form Substances 0.000 claims description 5
- 239000007937 lozenge Substances 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 229960005434 oxybutynin Drugs 0.000 claims description 2
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 55
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 55
- 230000007958 sleep Effects 0.000 description 20
- -1 Daredarin Chemical compound 0.000 description 19
- 150000001875 compounds Chemical class 0.000 description 14
- GJJFMKBJSRMPLA-HIFRSBDPSA-N (1R,2S)-2-(aminomethyl)-N,N-diethyl-1-phenyl-1-cyclopropanecarboxamide Chemical compound C=1C=CC=CC=1[C@@]1(C(=O)N(CC)CC)C[C@@H]1CN GJJFMKBJSRMPLA-HIFRSBDPSA-N 0.000 description 10
- 239000003112 inhibitor Substances 0.000 description 10
- 229960003770 reboxetine Drugs 0.000 description 10
- CBQGYUDMJHNJBX-RTBURBONSA-N reboxetine Chemical compound CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CBQGYUDMJHNJBX-RTBURBONSA-N 0.000 description 10
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 9
- 229960002748 norepinephrine Drugs 0.000 description 9
- SFLSHLFXELFNJZ-UHFFFAOYSA-N norepinephrine Natural products NCC(O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-UHFFFAOYSA-N 0.000 description 9
- 208000008784 apnea Diseases 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 206010021079 Hypopnoea Diseases 0.000 description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 7
- 229940079593 drug Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 230000001225 therapeutic effect Effects 0.000 description 7
- 229960001475 zolpidem Drugs 0.000 description 7
- ZAFYATHCZYHLPB-UHFFFAOYSA-N zolpidem Chemical compound N1=C2C=CC(C)=CN2C(CC(=O)N(C)C)=C1C1=CC=C(C)C=C1 ZAFYATHCZYHLPB-UHFFFAOYSA-N 0.000 description 7
- 230000037007 arousal Effects 0.000 description 6
- 239000003326 hypnotic agent Substances 0.000 description 6
- 229950004863 lortalamine Drugs 0.000 description 6
- MJRPHRMGEKCADU-JVLSTEMRSA-N lortalamine Chemical compound C12=CC(Cl)=CC=C2O[C@]23CCN(C)C[C@@H]2[C@H]1CC(=O)N3 MJRPHRMGEKCADU-JVLSTEMRSA-N 0.000 description 6
- BRPOADLGOFPKKJ-UHFFFAOYSA-N tandamine Chemical compound C12=CC=CC=C2N(CC)C2=C1CCSC2(C)CCN(C)C BRPOADLGOFPKKJ-UHFFFAOYSA-N 0.000 description 6
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 description 5
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 5
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 5
- 241000282412 Homo Species 0.000 description 5
- DUGOZIWVEXMGBE-UHFFFAOYSA-N Methylphenidate Chemical compound C=1C=CC=CC=1C(C(=O)OC)C1CCCCN1 DUGOZIWVEXMGBE-UHFFFAOYSA-N 0.000 description 5
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 5
- KYYIDSXMWOZKMP-UHFFFAOYSA-N O-desmethylvenlafaxine Chemical compound C1CCCCC1(O)C(CN(C)C)C1=CC=C(O)C=C1 KYYIDSXMWOZKMP-UHFFFAOYSA-N 0.000 description 5
- MFOCDFTXLCYLKU-CMPLNLGQSA-N Phendimetrazine Chemical compound O1CCN(C)[C@@H](C)[C@@H]1C1=CC=CC=C1 MFOCDFTXLCYLKU-CMPLNLGQSA-N 0.000 description 5
- 229960000836 amitriptyline Drugs 0.000 description 5
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 5
- 229960002519 amoxapine Drugs 0.000 description 5
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 5
- 229960001058 bupropion Drugs 0.000 description 5
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 5
- HLOCJJORRHQDKS-UHFFFAOYSA-N cp-39,332 Chemical compound C12=CC=CC=C2CC(NC)CC1C1=CC=CC=C1 HLOCJJORRHQDKS-UHFFFAOYSA-N 0.000 description 5
- 229960003914 desipramine Drugs 0.000 description 5
- 229960001623 desvenlafaxine Drugs 0.000 description 5
- XXEPPPIWZFICOJ-UHFFFAOYSA-N diethylpropion Chemical compound CCN(CC)C(C)C(=O)C1=CC=CC=C1 XXEPPPIWZFICOJ-UHFFFAOYSA-N 0.000 description 5
- 229960004890 diethylpropion Drugs 0.000 description 5
- 208000035475 disorder Diseases 0.000 description 5
- 229960005426 doxepin Drugs 0.000 description 5
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 5
- 229960002866 duloxetine Drugs 0.000 description 5
- 229960004801 imipramine Drugs 0.000 description 5
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 5
- 229960000685 levomilnacipran Drugs 0.000 description 5
- 229960004090 maprotiline Drugs 0.000 description 5
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 5
- 229960000600 milnacipran Drugs 0.000 description 5
- 210000003205 muscle Anatomy 0.000 description 5
- 229960001800 nefazodone Drugs 0.000 description 5
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 5
- ITJNARMNRKSWTA-UHFFFAOYSA-N nisoxetine Chemical compound C=1C=CC=CC=1C(CCNC)OC1=CC=CC=C1OC ITJNARMNRKSWTA-UHFFFAOYSA-N 0.000 description 5
- 229950004211 nisoxetine Drugs 0.000 description 5
- 229960001158 nortriptyline Drugs 0.000 description 5
- 229960000436 phendimetrazine Drugs 0.000 description 5
- 239000000902 placebo Substances 0.000 description 5
- 229940068196 placebo Drugs 0.000 description 5
- 229960002601 protriptyline Drugs 0.000 description 5
- BWPIARFWQZKAIA-UHFFFAOYSA-N protriptyline Chemical compound C1=CC2=CC=CC=C2C(CCCNC)C2=CC=CC=C21 BWPIARFWQZKAIA-UHFFFAOYSA-N 0.000 description 5
- LJBBMCNHIUJBDU-UHFFFAOYSA-N talopram Chemical compound O1C(C)(C)C2=CC=CC=C2C1(CCCNC)C1=CC=CC=C1 LJBBMCNHIUJBDU-UHFFFAOYSA-N 0.000 description 5
- 229950007352 talopram Drugs 0.000 description 5
- 229950006964 tandamine Drugs 0.000 description 5
- KWTWDQCKEHXFFR-SMDDNHRTSA-N tapentadol Chemical compound CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 KWTWDQCKEHXFFR-SMDDNHRTSA-N 0.000 description 5
- 229960005126 tapentadol Drugs 0.000 description 5
- 229960004688 venlafaxine Drugs 0.000 description 5
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 5
- 229960001255 viloxazine Drugs 0.000 description 5
- 238000004113 cell culture Methods 0.000 description 4
- 230000003247 decreasing effect Effects 0.000 description 4
- DUGOZIWVEXMGBE-CHWSQXEVSA-N dexmethylphenidate Chemical compound C([C@@H]1[C@H](C(=O)OC)C=2C=CC=CC=2)CCCN1 DUGOZIWVEXMGBE-CHWSQXEVSA-N 0.000 description 4
- 229960001042 dexmethylphenidate Drugs 0.000 description 4
- 230000000147 hypnotic effect Effects 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 229960001344 methylphenidate Drugs 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- CBQGYUDMJHNJBX-OALUTQOASA-N (2S)-2-[(S)-(2-ethoxyphenoxy)-phenylmethyl]morpholine Chemical compound CCOC1=CC=CC=C1O[C@@H](C=1C=CC=CC=1)[C@H]1OCCNC1 CBQGYUDMJHNJBX-OALUTQOASA-N 0.000 description 3
- 206010021143 Hypoxia Diseases 0.000 description 3
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 210000000038 chest Anatomy 0.000 description 3
- 229950008247 esreboxetine Drugs 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- RCOBKSKAZMVBHT-TVQRCGJNSA-N radafaxine Chemical compound C[C@@H]1NC(C)(C)CO[C@@]1(O)C1=CC=CC(Cl)=C1 RCOBKSKAZMVBHT-TVQRCGJNSA-N 0.000 description 3
- 229950010561 radafaxine Drugs 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000029058 respiratory gaseous exchange Effects 0.000 description 3
- FKHYYOUFMJBLAF-UHFFFAOYSA-N 3-(3,3-dimethyl-1-phenyl-2-benzothiophen-1-yl)-n-methylpropan-1-amine Chemical compound S1C(C)(C)C2=CC=CC=C2C1(CCCNC)C1=CC=CC=C1 FKHYYOUFMJBLAF-UHFFFAOYSA-N 0.000 description 2
- UGJMXCAKCUNAIE-UHFFFAOYSA-N Gabapentin Chemical compound OC(=O)CC1(CN)CCCCC1 UGJMXCAKCUNAIE-UHFFFAOYSA-N 0.000 description 2
- 108010064719 Oxyhemoglobins Proteins 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- HBGWAZBZXJBYQD-UHFFFAOYSA-N amedalin Chemical compound C12=CC=CC=C2C(CCCNC)(C)C(=O)N1C1=CC=CC=C1 HBGWAZBZXJBYQD-UHFFFAOYSA-N 0.000 description 2
- 229950000203 amedalin Drugs 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 238000003556 assay Methods 0.000 description 2
- 229940002047 atomoxetine 80 mg Drugs 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000008602 contraction Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- CPBHSHYQQLFAPW-ZWKOTPCHSA-N edivoxetine Chemical compound COC1=CC=C(F)C=C1C[C@](O)([C@H]1OCCNC1)C1CCOCC1 CPBHSHYQQLFAPW-ZWKOTPCHSA-N 0.000 description 2
- 229950003015 edivoxetine Drugs 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 208000018875 hypoxemia Diseases 0.000 description 2
- 239000006210 lotion Substances 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- OSWPMRLSEDHDFF-UHFFFAOYSA-N methyl salicylate Chemical compound COC(=O)C1=CC=CC=C1O OSWPMRLSEDHDFF-UHFFFAOYSA-N 0.000 description 2
- 239000003149 muscarinic antagonist Substances 0.000 description 2
- 239000002674 ointment Substances 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 210000001184 pharyngeal muscle Anatomy 0.000 description 2
- 230000036385 rapid eye movement (rem) sleep Effects 0.000 description 2
- 230000004622 sleep time Effects 0.000 description 2
- 239000008107 starch Substances 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 229950003014 teniloxazine Drugs 0.000 description 2
- OILWWIVKIDXCIB-UHFFFAOYSA-N teniloxazine Chemical compound C1NCCOC1COC1=CC=CC=C1CC1=CC=CS1 OILWWIVKIDXCIB-UHFFFAOYSA-N 0.000 description 2
- 238000009423 ventilation Methods 0.000 description 2
- 230000003519 ventilatory effect Effects 0.000 description 2
- CGTZMJIMMUNLQD-STYNFMPRSA-N (2r)-2-[(r)-(2-ethoxyphenoxy)-phenylmethyl]morpholine;methanesulfonic acid Chemical compound CS(O)(=O)=O.CCOC1=CC=CC=C1O[C@H](C=1C=CC=CC=1)[C@@H]1OCCNC1 CGTZMJIMMUNLQD-STYNFMPRSA-N 0.000 description 1
- OOBHFESNSZDWIU-GXSJLCMTSA-N (2s,3s)-3-methyl-2-phenylmorpholine Chemical compound C[C@@H]1NCCO[C@H]1C1=CC=CC=C1 OOBHFESNSZDWIU-GXSJLCMTSA-N 0.000 description 1
- ONQAJVWRFPPADI-BTJKTKAUSA-N (z)-but-2-enedioic acid;2-[[2-(thiophen-2-ylmethyl)phenoxy]methyl]morpholine Chemical compound OC(=O)\C=C/C(O)=O.C1NCCOC1COC1=CC=CC=C1CC1=CC=CS1 ONQAJVWRFPPADI-BTJKTKAUSA-N 0.000 description 1
- HJOCKFVCMLCPTP-UHFFFAOYSA-N 2-[(2-ethoxyphenoxy)methyl]morpholine;hydron;chloride Chemical compound Cl.CCOC1=CC=CC=C1OCC1OCCNC1 HJOCKFVCMLCPTP-UHFFFAOYSA-N 0.000 description 1
- ZELFLGGRLLOERW-YECZQDJWSA-N 3-[(2r,3r)-1-(dimethylamino)-2-methylpentan-3-yl]phenol;hydrochloride Chemical compound Cl.CN(C)C[C@H](C)[C@@H](CC)C1=CC=CC(O)=C1 ZELFLGGRLLOERW-YECZQDJWSA-N 0.000 description 1
- SJZRECIVHVDYJC-UHFFFAOYSA-N 4-hydroxybutyric acid Chemical compound OCCCC(O)=O SJZRECIVHVDYJC-UHFFFAOYSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 108010035532 Collagen Proteins 0.000 description 1
- 208000007590 Disorders of Excessive Somnolence Diseases 0.000 description 1
- XIQVNETUBQGFHX-UHFFFAOYSA-N Ditropan Chemical compound C=1C=CC=CC=1C(O)(C(=O)OCC#CCN(CC)CC)C1CCCCC1 XIQVNETUBQGFHX-UHFFFAOYSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 244000246386 Mentha pulegium Species 0.000 description 1
- 235000016257 Mentha pulegium Nutrition 0.000 description 1
- 235000004357 Mentha x piperita Nutrition 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 208000008589 Obesity Diseases 0.000 description 1
- 229920002732 Polyanhydride Polymers 0.000 description 1
- 229920000954 Polyglycolide Polymers 0.000 description 1
- 229920001710 Polyorthoester Polymers 0.000 description 1
- 206010039203 Road traffic accident Diseases 0.000 description 1
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 1
- 208000010340 Sleep Deprivation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 206010041349 Somnolence Diseases 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 1
- 240000008042 Zea mays Species 0.000 description 1
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 1
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 230000003187 abdominal effect Effects 0.000 description 1
- 210000003815 abdominal wall Anatomy 0.000 description 1
- 239000003070 absorption delaying agent Substances 0.000 description 1
- 230000001464 adherent effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 235000010443 alginic acid Nutrition 0.000 description 1
- 229920000615 alginic acid Polymers 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003429 antifungal agent Substances 0.000 description 1
- 210000004082 barrier epithelial cell Anatomy 0.000 description 1
- 229940049706 benzodiazepine Drugs 0.000 description 1
- 150000001557 benzodiazepines Chemical class 0.000 description 1
- 229920000249 biocompatible polymer Polymers 0.000 description 1
- 229920002988 biodegradable polymer Polymers 0.000 description 1
- 210000000988 bone and bone Anatomy 0.000 description 1
- RICLFGYGYQXUFH-UHFFFAOYSA-N buspirone hydrochloride Chemical compound [H+].[Cl-].C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 RICLFGYGYQXUFH-UHFFFAOYSA-N 0.000 description 1
- DQXBYHZEEUGOBF-UHFFFAOYSA-N but-3-enoic acid;ethene Chemical compound C=C.OC(=O)CC=C DQXBYHZEEUGOBF-UHFFFAOYSA-N 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229950009468 ciclazindol Drugs 0.000 description 1
- VKQDZNZTPGLGFD-UHFFFAOYSA-N ciclazindol Chemical compound C12=NCCCN2C2=CC=CC=C2C1(O)C1=CC=CC(Cl)=C1 VKQDZNZTPGLGFD-UHFFFAOYSA-N 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 229940075614 colloidal silicon dioxide Drugs 0.000 description 1
- 238000013270 controlled release Methods 0.000 description 1
- 235000005822 corn Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002612 dispersion medium Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 210000002409 epiglottis Anatomy 0.000 description 1
- 230000004890 epithelial barrier function Effects 0.000 description 1
- XIQVNETUBQGFHX-JOCHJYFZSA-N esoxybutynin Chemical compound C1([C@@](O)(C(=O)OCC#CCN(CC)CC)C=2C=CC=CC=2)CCCCC1 XIQVNETUBQGFHX-JOCHJYFZSA-N 0.000 description 1
- 229960001578 eszopiclone Drugs 0.000 description 1
- GBBSUAFBMRNDJC-INIZCTEOSA-N eszopiclone Chemical compound C1CN(C)CCN1C(=O)O[C@H]1C2=NC=CN=C2C(=O)N1C1=CC=C(Cl)C=N1 GBBSUAFBMRNDJC-INIZCTEOSA-N 0.000 description 1
- 239000005038 ethylene vinyl acetate Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 229960002870 gabapentin Drugs 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 235000001050 hortel pimenta Nutrition 0.000 description 1
- 230000007954 hypoxia Effects 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 239000003701 inert diluent Substances 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 239000007951 isotonicity adjuster Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229950006048 manifaxine Drugs 0.000 description 1
- OZGPVYJHWWPEFT-RGNHYFCHSA-N manifaxine Chemical compound C[C@@H]1N[C@H](C)CO[C@@]1(O)C1=CC(F)=CC(F)=C1 OZGPVYJHWWPEFT-RGNHYFCHSA-N 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- STZCRXQWRGQSJD-GEEYTBSJSA-M methyl orange Chemical compound [Na+].C1=CC(N(C)C)=CC=C1\N=N\C1=CC=C(S([O-])(=O)=O)C=C1 STZCRXQWRGQSJD-GEEYTBSJSA-M 0.000 description 1
- 229940012189 methyl orange Drugs 0.000 description 1
- 229960001047 methyl salicylate Drugs 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 229940083311 nucynta Drugs 0.000 description 1
- 235000020824 obesity Nutrition 0.000 description 1
- 230000000414 obstructive effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 238000011458 pharmacological treatment Methods 0.000 description 1
- 210000003800 pharynx Anatomy 0.000 description 1
- 229960003209 phenmetrazine Drugs 0.000 description 1
- 230000036470 plasma concentration Effects 0.000 description 1
- 229920001200 poly(ethylene-vinyl acetate) Polymers 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 239000004633 polyglycolic acid Substances 0.000 description 1
- 239000004626 polylactic acid Substances 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 210000003019 respiratory muscle Anatomy 0.000 description 1
- 230000004043 responsiveness Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 229940081974 saccharin Drugs 0.000 description 1
- 235000019204 saccharin Nutrition 0.000 description 1
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 description 1
- 239000000932 sedative agent Substances 0.000 description 1
- 229940125723 sedative agent Drugs 0.000 description 1
- 239000003772 serotonin uptake inhibitor Substances 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 229940012488 strattera Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000007910 systemic administration Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229950002139 talsupram Drugs 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 210000000115 thoracic cavity Anatomy 0.000 description 1
- 210000000779 thoracic wall Anatomy 0.000 description 1
- 229960001918 tiagabine Drugs 0.000 description 1
- PBJUNZJWGZTSKL-MRXNPFEDSA-N tiagabine Chemical compound C1=CSC(C(=CCCN2C[C@@H](CCC2)C(O)=O)C2=C(C=CS2)C)=C1C PBJUNZJWGZTSKL-MRXNPFEDSA-N 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 230000001988 toxicity Effects 0.000 description 1
- 231100000419 toxicity Toxicity 0.000 description 1
- 238000011277 treatment modality Methods 0.000 description 1
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 1
- 229940051225 xyrem Drugs 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Emergency Medicine (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Priority Applications (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2023183525A JP2023181322A (ja) | 2018-01-30 | 2023-10-25 | 睡眠時無呼吸を治療するための方法および組成物 |
| JP2025138640A JP2025159230A (ja) | 2018-01-30 | 2025-08-22 | 睡眠時無呼吸を治療するための方法および組成物 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862623892P | 2018-01-30 | 2018-01-30 | |
| US62/623,892 | 2018-01-30 | ||
| PCT/US2019/015781 WO2019152475A1 (en) | 2018-01-30 | 2019-01-30 | Methods and compositions for treating sleep apnea |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023183525A Division JP2023181322A (ja) | 2018-01-30 | 2023-10-25 | 睡眠時無呼吸を治療するための方法および組成物 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021516218A JP2021516218A (ja) | 2021-07-01 |
| JP7422666B2 true JP7422666B2 (ja) | 2024-01-26 |
Family
ID=65441079
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020542075A Active JP7422666B2 (ja) | 2018-01-30 | 2019-01-30 | 睡眠時無呼吸を治療するための方法および組成物 |
| JP2023183525A Pending JP2023181322A (ja) | 2018-01-30 | 2023-10-25 | 睡眠時無呼吸を治療するための方法および組成物 |
| JP2025138640A Pending JP2025159230A (ja) | 2018-01-30 | 2025-08-22 | 睡眠時無呼吸を治療するための方法および組成物 |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023183525A Pending JP2023181322A (ja) | 2018-01-30 | 2023-10-25 | 睡眠時無呼吸を治療するための方法および組成物 |
| JP2025138640A Pending JP2025159230A (ja) | 2018-01-30 | 2025-08-22 | 睡眠時無呼吸を治療するための方法および組成物 |
Country Status (27)
| Country | Link |
|---|---|
| US (6) | US11911351B2 (https=) |
| EP (2) | EP3746126B1 (https=) |
| JP (3) | JP7422666B2 (https=) |
| KR (2) | KR102874891B1 (https=) |
| CN (2) | CN111670050A (https=) |
| AU (2) | AU2019214891B2 (https=) |
| BR (1) | BR112020015316A2 (https=) |
| CA (1) | CA3089712A1 (https=) |
| DK (1) | DK3746126T3 (https=) |
| EA (1) | EA202091597A1 (https=) |
| ES (1) | ES2991425T3 (https=) |
| FI (1) | FI3746126T3 (https=) |
| HR (1) | HRP20241412T1 (https=) |
| HU (1) | HUE068505T2 (https=) |
| IL (1) | IL276247A (https=) |
| LT (1) | LT3746126T (https=) |
| MA (1) | MA52861B1 (https=) |
| MD (1) | MD3746126T2 (https=) |
| MX (2) | MX2020008086A (https=) |
| PL (1) | PL3746126T3 (https=) |
| PT (1) | PT3746126T (https=) |
| RS (1) | RS66104B1 (https=) |
| SG (1) | SG11202007226UA (https=) |
| SI (1) | SI3746126T1 (https=) |
| SM (1) | SMT202400400T1 (https=) |
| UA (1) | UA129618C2 (https=) |
| WO (1) | WO2019152475A1 (https=) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GEAP202416602A (en) * | 2017-04-28 | 2024-10-10 | Brigham & Womens Hospital Inc | Methods and compositions for treating sleep apnea |
| CN118557736A (zh) | 2019-02-08 | 2024-08-30 | 布里格姆妇女医院 | 用于治疗睡眠呼吸暂停的方法和组合物 |
| US20220362221A1 (en) * | 2019-11-04 | 2022-11-17 | Apnimed, Inc. (Delaware) | Combination pharmacological interventions for multiple mechanisms of obstructive sleep apnea |
| WO2022069250A1 (en) | 2020-09-30 | 2022-04-07 | Koninklijke Philips N.V. | Methods and systems for performing dose titration |
| AU2022231133A1 (en) * | 2021-03-04 | 2023-09-21 | Apnimed, Inc. (Delaware) | Combination of reboxetine and a muscarinic receptor antagonist (mra) for use in treating sleep apnea |
| WO2022204228A1 (en) * | 2021-03-24 | 2022-09-29 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
| EP4334281A1 (en) | 2021-05-04 | 2024-03-13 | Apnimed, Inc. (Delaware) | Solid forms of (r)-oxybutynin d-malate |
| US20240277719A1 (en) * | 2021-06-17 | 2024-08-22 | Apnimed, Inc. (Delaware) | Norepinephrine reuptake inhibitors for treating sleep apnea |
| KR20240124995A (ko) | 2021-12-22 | 2024-08-19 | 바이엘 악티엔게젤샤프트 | 수면 무호흡의 치료를 위한 a2-아드레날린수용체 하위유형 c (알파-2c) 길항제와 노르에피네프린 재흡수 억제제의 조합물 |
| CA3259602A1 (en) | 2021-12-22 | 2023-06-29 | Bayer Aktiengesellschaft | Combination of an .alpha.2-adrenoceptor subtype c (alpha-2c) antagonists with a muscarinic receptor antagonist for the treatment of sleep apnea |
| EP4522149A1 (en) * | 2022-05-13 | 2025-03-19 | Apnimed, Inc. (Delaware) | Methods and compositions for treating sleep apnea |
| KR20250000641A (ko) * | 2023-06-27 | 2025-01-03 | 주식회사 아스트로젠 | 수면장애 및/또는 수면장애 관련 질환을 예방, 개선 또는 치료하는 방법 |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003523382A (ja) | 2000-02-24 | 2003-08-05 | ファルマシア・アンド・アップジョン・カンパニー | 新規な薬物の組合せ |
| JP2012176958A (ja) | 2012-04-20 | 2012-09-13 | Watson Pharmaceuticals Inc | （ｒ）−オキシブチニンおよび（ｒ）−デスエチルオキシブチニンによる平滑筋機能亢進の処置 |
| JP2020517719A (ja) | 2017-04-28 | 2020-06-18 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | 睡眠時無呼吸を治療する方法及び組成物 |
Family Cites Families (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL124473C (https=) | 1960-07-26 | |||
| US4522811A (en) | 1982-07-08 | 1985-06-11 | Syntex (U.S.A.) Inc. | Serial injection of muramyldipeptides and liposomes enhances the anti-infective activity of muramyldipeptides |
| DE69636393T2 (de) | 1995-10-24 | 2006-12-07 | Grünenthal GmbH | Montirelin zur verhinderung der schlafapnoe |
| US20020155113A1 (en) | 2001-03-13 | 2002-10-24 | Miyoung Chun | Methods for treating or preventing cardiovascular disorders by modulating metalloprotease function |
| US20030060513A1 (en) | 2001-09-27 | 2003-03-27 | Arneric Stephen P. | Pharmaceutical composition |
| US20030185882A1 (en) * | 2001-11-06 | 2003-10-02 | Vergez Juan A. | Pharmaceutical compositions containing oxybutynin |
| US20040235925A1 (en) | 2002-12-17 | 2004-11-25 | Pharmacia Corporation | Method for the treatment, prevention, or inhibition of a CNS disorder and/or pain and inflammation using a combination of duloxetine, venlafaxine or atomoxetine and a cyclooxygenase-2 selective inhibitor and compositions thereof |
| JP2006524708A (ja) | 2003-04-25 | 2006-11-02 | インディヴァス ファーマシューティカルズ，インコーポレーテッド | 塩化トロスピウムの投与により連続睡眠を促進するための方法 |
| PT1696931E (pt) | 2003-12-22 | 2009-06-12 | Acadia Pharm Inc | Análogos diaril[a,d]ciclo-hepteno substituídos com amino utilizados como agonistas muscarínicos e métodos de tratamento de perturbações neuropsiquiátricas |
| US20060039866A1 (en) | 2004-08-20 | 2006-02-23 | Cypress Bioscience, Inc. | Method for treating sleep-related breathing disorders |
| US8252321B2 (en) | 2004-09-13 | 2012-08-28 | Chrono Therapeutics, Inc. | Biosynchronous transdermal drug delivery for longevity, anti-aging, fatigue management, obesity, weight loss, weight management, delivery of nutraceuticals, and the treatment of hyperglycemia, alzheimer's disease, sleep disorders, parkinson's disease, aids, epilepsy, attention deficit disorder, nicotine addiction, cancer, headache and pain control, asthma, angina, hypertension, depression, cold, flu and the like |
| EP1827450A4 (en) | 2004-11-17 | 2009-04-22 | Cypress Bioscience Inc | METHOD FOR REDUCING THE SIDE EFFECTS OF TREATMENT WITH MIRTAZAPINE |
| CN101132777A (zh) | 2004-12-20 | 2008-02-27 | 科利吉姆制药公司 | 用于睡眠障碍的药物组合物 |
| US20080009538A1 (en) | 2005-03-21 | 2008-01-10 | Phil Skolnick | Methods and compositions for the treatment of urinary incontinence |
| CA2603920A1 (en) | 2005-04-15 | 2006-10-26 | The Board Of Trustees Of The University Of Illinois | Pharmacological treatment for sleep apnea |
| US20070021927A1 (en) | 2005-07-21 | 2007-01-25 | Searete Llc, A Limited Liability Corporation Of The State Of Delaware | Selective resonance of chemical structures |
| FR2889811B1 (fr) | 2005-08-19 | 2009-10-09 | Sanofi Aventis Sa | Association d'un agent hypnotique a duree d'action longue et d'un agent hypnotique a duree d'action courte, composition pharmaceutique la contenant et son application en therapeutique. |
| PL2083811T3 (pl) | 2006-11-22 | 2017-05-31 | Clinical Research Associates, Llc | Sposoby leczenia zespołu downa, zespołu łamliwego chromosomu x oraz autyzmu |
| WO2008122019A1 (en) | 2007-04-02 | 2008-10-09 | Cypress Biosciences, Inc. | Improving the tolerability of both mirtazapine and reboxetine by using them in combination |
| EP2142183A2 (en) | 2007-04-09 | 2010-01-13 | Sepracor Inc. | Methods and compositions comprising desvenlafaxine or duloxetine for treating sleep-related breathing disorders |
| US8415390B2 (en) | 2008-05-30 | 2013-04-09 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
| US9119777B2 (en) | 2008-05-30 | 2015-09-01 | Microdose Therapeutx, Inc. | Methods and compositions for administration of oxybutynin |
| US20090048233A1 (en) | 2007-08-16 | 2009-02-19 | Cypress Biosciences, Inc. | Enhancing the Tolerability of a Seratonin Antagonist and a NSRI, a SNRI or a RIMA by Using Them in Combination |
| AR069875A1 (es) | 2007-12-21 | 2010-02-24 | Eurand Inc | Composiciones de temazepam para tabletas de desintegracion oral y metodo de preparacion |
| US20100204058A1 (en) | 2009-01-28 | 2010-08-12 | Howard Yuan-Hao Chang | Profiling for Determination of Response to Treatment for Inflammatory Disease |
| EP2552205A4 (en) | 2010-04-01 | 2014-01-01 | Theravida Inc | PROCESS FOR INCREASING SLEEP QUALITY |
| JP2014503593A (ja) | 2011-01-28 | 2014-02-13 | ファンタスティック・メディカル・リサーチ・インスティテュート・エルエルシー | 閉塞性睡眠時無呼吸を処置するための方法 |
| DK2964185T3 (da) | 2013-03-05 | 2022-02-14 | Requis Pharmaceuticals Inc | Præparater til behandlingen af søvnrelaterede luftvejslidelser |
| US20170304286A1 (en) | 2014-10-24 | 2017-10-26 | Launx Biomedical Co., Ltd. | New indication of paroxetine pharmaceutical composition for treating cancer |
| MX373319B (es) | 2015-04-27 | 2020-06-13 | Arena Pharm Inc | Derivados de hexahidro-[1-4]diazepino[6,7,1-hi]indol-8-carboxamida como agonistas del receptor 5-ht2c y el uso de los mismos en el tratamiento de enfermedades relacionadas con dicho receptor. |
| ES2925951T3 (es) | 2015-07-22 | 2022-10-20 | John Hsu | Composición que comprende un agente terapéutico y un estimulante respiratorio y métodos para su uso |
| WO2017031319A1 (en) | 2015-08-18 | 2017-02-23 | Massachusetts Institute Of Technology | Noradrenergic drug treatment of obstructive sleep apnea |
| AR114350A1 (es) | 2018-01-31 | 2020-08-26 | Res Institute At Nationwide ChildrenS Hospital | Terapia genética para la distrofia muscular de cinturas del tipo 2c |
| CN118557736A (zh) | 2019-02-08 | 2024-08-30 | 布里格姆妇女医院 | 用于治疗睡眠呼吸暂停的方法和组合物 |
-
2019
- 2019-01-30 KR KR1020207024790A patent/KR102874891B1/ko active Active
- 2019-01-30 PL PL19705634.4T patent/PL3746126T3/pl unknown
- 2019-01-30 RS RS20241137A patent/RS66104B1/sr unknown
- 2019-01-30 JP JP2020542075A patent/JP7422666B2/ja active Active
- 2019-01-30 HR HRP20241412TT patent/HRP20241412T1/hr unknown
- 2019-01-30 US US16/965,960 patent/US11911351B2/en active Active
- 2019-01-30 EA EA202091597A patent/EA202091597A1/ru unknown
- 2019-01-30 UA UAA202004819A patent/UA129618C2/uk unknown
- 2019-01-30 HU HUE19705634A patent/HUE068505T2/hu unknown
- 2019-01-30 CA CA3089712A patent/CA3089712A1/en active Pending
- 2019-01-30 MA MA52861A patent/MA52861B1/fr unknown
- 2019-01-30 DK DK19705634.4T patent/DK3746126T3/da active
- 2019-01-30 SI SI201930847T patent/SI3746126T1/sl unknown
- 2019-01-30 KR KR1020257034519A patent/KR20250156197A/ko active Pending
- 2019-01-30 MX MX2020008086A patent/MX2020008086A/es unknown
- 2019-01-30 SM SM20240400T patent/SMT202400400T1/it unknown
- 2019-01-30 BR BR112020015316-8A patent/BR112020015316A2/pt unknown
- 2019-01-30 MD MDE20201230T patent/MD3746126T2/ro unknown
- 2019-01-30 PT PT197056344T patent/PT3746126T/pt unknown
- 2019-01-30 SG SG11202007226UA patent/SG11202007226UA/en unknown
- 2019-01-30 LT LTEPPCT/US2019/015781T patent/LT3746126T/lt unknown
- 2019-01-30 EP EP19705634.4A patent/EP3746126B1/en active Active
- 2019-01-30 ES ES19705634T patent/ES2991425T3/es active Active
- 2019-01-30 CN CN201980010884.XA patent/CN111670050A/zh active Pending
- 2019-01-30 AU AU2019214891A patent/AU2019214891B2/en active Active
- 2019-01-30 CN CN202410467832.8A patent/CN118384147A/zh active Pending
- 2019-01-30 FI FIEP19705634.4T patent/FI3746126T3/fi active
- 2019-01-30 EP EP24183712.9A patent/EP4445951A3/en active Pending
- 2019-01-30 WO PCT/US2019/015781 patent/WO2019152475A1/en not_active Ceased
-
2020
- 2020-07-23 IL IL276247A patent/IL276247A/en unknown
- 2020-07-30 MX MX2024001713A patent/MX2024001713A/es unknown
-
2022
- 2022-08-05 US US17/882,318 patent/US20220378724A1/en not_active Abandoned
-
2023
- 2023-10-25 JP JP2023183525A patent/JP2023181322A/ja active Pending
-
2024
- 2024-01-23 US US18/419,974 patent/US20240156753A1/en not_active Abandoned
- 2024-08-06 US US18/795,245 patent/US20240390299A1/en not_active Abandoned
- 2024-10-25 AU AU2024227631A patent/AU2024227631A1/en active Pending
-
2025
- 2025-02-17 US US19/055,172 patent/US20250186371A1/en not_active Abandoned
- 2025-08-22 JP JP2025138640A patent/JP2025159230A/ja active Pending
- 2025-10-02 US US19/348,331 patent/US20260027070A1/en active Pending
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2003523382A (ja) | 2000-02-24 | 2003-08-05 | ファルマシア・アンド・アップジョン・カンパニー | 新規な薬物の組合せ |
| JP2012176958A (ja) | 2012-04-20 | 2012-09-13 | Watson Pharmaceuticals Inc | （ｒ）−オキシブチニンおよび（ｒ）−デスエチルオキシブチニンによる平滑筋機能亢進の処置 |
| JP2020517719A (ja) | 2017-04-28 | 2020-06-18 | ザ ブリガム アンド ウィメンズ ホスピタル インコーポレイテッドＴｈｅ Ｂｒｉｇｈａｍ ａｎｄ Ｗｏｍｅｎ’ｓ Ｈｏｓｐｉｔａｌ， Ｉｎｃ． | 睡眠時無呼吸を治療する方法及び組成物 |
Non-Patent Citations (2)
| Title |
|---|
| Atomoxetine and Oxybutynin in Obstructive Sleep Apnea (ATOSA) / Study NCT02908529 on Date: January 17, 2018 (v3)，ClinicalTrials.gov archive [online]，U. S. National Library of Medicine，2018年01月17日，https://clinicaltrials.gov/ct2/history/NCT02908529?A=3&B=3&C=merged#StudyPageTop |
| The Journal of Pharmacology and Experimental Therapeutics，1991年，Vol.256, No.2，p.562-567 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7422666B2 (ja) | 睡眠時無呼吸を治療するための方法および組成物 | |
| US20260007618A1 (en) | Methods and compositions for treating sleep apnea | |
| US20250114321A1 (en) | Methods and compositions for treating sleep apnea | |
| US20230135373A1 (en) | Methods and compositions for treating sleep apnea | |
| HK40117857A (en) | Methods and compositions for treating sleep apnea | |
| HK40120547A (zh) | 用於治疗睡眠呼吸暂停的方法和组合物 | |
| HK40031779A (en) | Methods and compositions for treating sleep apnea or simple snoring | |
| HK40031779B (en) | Methods and compositions for treating sleep apnea or simple snoring | |
| HK40013951A (en) | Methods and compositions for treating sleep apnea | |
| OA19434A (en) | Methods and compositions for treating sleep apnea. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210426 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220104 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20221021 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20221102 |
|
| A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230120 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20230502 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20230727 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20231025 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20231027 |
|
| A911 | Transfer to examiner for re-examination before appeal (zenchi) |
Free format text: JAPANESE INTERMEDIATE CODE: A911 Effective date: 20231116 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20231218 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20240116 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 7422666 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| S531 | Written request for registration of change of domicile |
Free format text: JAPANESE INTERMEDIATE CODE: R313531 |
|
| R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |